Bristol Myers Squibb announced a partnership with Anthropic to deploy Claude across its global operations, with plans to integrate the system across research, clinical development, manufacturing, commercial operations, and corporate functions. BMS said it intends to go beyond chat-style tools by embedding AI agents into day-to-day workflows. Under the collaboration, BMS will focus on accelerating engineering via Claude Code, adding AI agent layers to drug development workflows, and supporting end-to-end clinical documentation and regulatory submissions. The company said the platform will serve more than 30,000 employees. The announcement signals that major sponsors are shifting from limited AI experiments to integrated “shared intelligence” stacks tied to operational processes, data governance, and regulatory deliverables.